<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805089</url>
  </required_header>
  <id_info>
    <org_study_id>05-305</org_study_id>
    <nct_id>NCT01805089</nct_id>
  </id_info>
  <brief_title>Melatonin Versus Placebo in Breast Cancer</brief_title>
  <official_title>A Randomized Trial of Oral Melatonin Supplementation in Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether melatonin taken every night can
      affect blood levels of estrogen or IGF (insulin-growth factor levels). Both IGF and estrogen
      are normally produced in the body and may influence breast cancer risk. Melatonin is also
      naturally produced in the body. Laboratory studies have shown that melatonin may decrease
      cancer growth and influence estrogen and IGF levels. Melatonin's effects on sleep, hot
      flashes, and mood will also be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you agree to participate in this study you will be asked to undergo a blood test to find
      out if you are eligible. Approximately 2 tablespoons of blood will be drawn. The blood test
      will check your health and menopausal status. This test will aslo be used to help measure
      any additional effects of the study drug on your body. If you have had a blood test
      recently, it may or may not have to be repeated. If these tests show that you are eligible
      to participate in the research study, you will begin the study. If you do not meet the
      eligibility criteria, you will not be able to participate.

      Because no one knows which of the study options is best, and all of the options are
      considered likely to work, you will be &quot;randomized&quot; into one of the study groups: melatonin
      or placebo.

      Randomization means that you are put into a group by chance. It is like flipping a coin.
      Neither you nor the research doctor will choose what group you will be in. You will have an
      equal chance of being placed in either group. Neither you nor the research doctor will know
      what group you are in. You will not know the identity of your study treatment until after
      the final research analysis has taken place. Once this has happened, you will be mailed a
      letter from the principal research doctor telling you which study drug you received while on
      study.

      You will be given a study drug and it will either contain melatonin or placebo (pills with
      no medical effect). You will take one tablet by mouth every night as close to 9:00 pm as
      possible. You should not make up missed doses. You will be given enough study drug to last 4
      months. You will also be given a study medication-dosing calendar to write down times you
      took the study drug for each month you are taking the study drug.

      Before taking the study drug, you will have blood tests to look at the level of estrogen and
      IGF in your blood. Approximately 2 tablespoons of blood will be drawn. At this visit, you
      will also be asked to complete a questionnaire that will take approximately 15 minutes.

      A member of the research study staff will check in by telephone once a month to monitor your
      experiences on the research study. You may also contact a member of the research study staff
      at any time if you have any questions or concerns.

      You should tell your research doctor if you are currently taking black cohosh, flaxseed or
      soy in pill or supplement form, as it may affect your participation in this research study.

      After you have completed approximately 4 months of study drug, you will return to clinic to
      see a member of the research study staff. At this visit you will have the following tests
      and procedures: You will have blood tests to look at the level of estrogen and IGF in your
      blood. Approximately 2 tablespoons of blood will be drawn. You must return your study
      medication-dosing calendar and all of your pill bottles at the end of the research study to
      a member of the research study staff. You wil also be asked to complete a questionnaire that
      will take about 15 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absolute plasma estradiol levels after 4 month course of melatonin or placebo, only 4 month level provided below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate compliance with a 4 month course of melatonin. Compliance was assessed via pill counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mood, Sleep Quality and Menopausal Symptoms From Baseline to 4 Months</measure>
    <time_frame>baseline and 4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mood was assessed by the Center for Epidemiologic studies Depression Scale. The scale measures depressive symptoms in 20 items. Each question has a 4 point answer (0-3) so the scale range is 0-60. A higher score indicates more depression. Sleep quality was assessed by the Pittsburgh Sleep Quality Index. There are 19 questions each with a 3 point answer. The questions are grouped into 7 subscales and each has a value from 0-3. The 7 subscales are then added together to yield a global score with a range of 0-21. Higher scores indicate worse sleep. Menopausal symptoms were assessed by NCCTG Hot Flash diary. Subjects track the number and severity of hot flashes daily for 1 week. Subjects grade the severity of the hot flashes on a scale of 1-4, with 1 being mild and 4 very severe. Frequency and the severity determine the score . The minimum score is 0 (no hot flashes) and there is no maximum score. A higher score indicates more severe hot flashes. There are no subscales or no units.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Melatonin 3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taken orally, once per day, at/around 9:00pm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taken orally, once per day, at/around 9:00pm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 3 mg</intervention_name>
    <description>Melatonin vs. Placebo</description>
    <arm_group_label>Melatonin 3 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Melatonin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of ductal carcinoma in situ, lobular carcinoma in situ or stages 1-3 breast
             cancer

          -  Not currently receiving chemotherapy or hormonal therapy

          -  Postmenopausal

        Exclusion Criteria:

          -  Stage IV breast cancer or systemic recurrences

          -  Prior malignancies of any type other than breast cancer, basal or squamous cell
             carcinoma of the skin or carcinoma in situ of the cervix

          -  Use of adjuvant hormonal therapy, oral estrogen or progesterone replacement therapy,
             lutenizing hormone releasing hormone agonists currently or within the past 60 days

          -  Concomitant use of beta-blockers

          -  Concomitant nightly use of sleep aids at bedtime

          -  Working more than one overnight shift per month on a regular basis

          -  Concomitant use of postmenopausal hormone replacement therapy

          -  Concomitant use of black cohosh, flaxseed or soy in pill or supplement form

          -  Use of any type of oral melatonin supplementation within the past 30 days

          -  Use of warfarin (coumadin) within the past 30 days

          -  Active seizure disorder requiring the use of daily anti-epileptic medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>March 3, 2015</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <firstreceived_results_date>April 30, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Wendy Chen, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melatonin 3mg</title>
          <description>Taken orally, once per day, at/around 9:00pm
Melatonin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Taken orally, once per day, at/around 9:00pm
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>Taken orally, once per day, at/around 9:00pm
Melatonin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Taken orally, once per day, at/around 9:00pm
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58" lower_limit="48" upper_limit="70"/>
                <measurement group_id="B2" value="60" lower_limit="38" upper_limit="71"/>
                <measurement group_id="B3" value="59" lower_limit="38" upper_limit="71"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="95"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="91"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Multi-racial</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Cancer Stage</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Stage 0</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage I</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage II</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage III</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Current Smoker</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-Smoker</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Former Smoker</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25.7" lower_limit="20.1" upper_limit="44.9"/>
                <measurement group_id="B2" value="25.0" lower_limit="19.1" upper_limit="39.6"/>
                <measurement group_id="B3" value="25.6" lower_limit="19.1" upper_limit="44.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Estradiol</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4.59" spread="4.03"/>
                <measurement group_id="B2" value="3.35" spread="2.19"/>
                <measurement group_id="B3" value="3.97" spread="3.29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Insulin-like Growth Factor 1</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="181.95" spread="60.22"/>
                <measurement group_id="B2" value="177.83" spread="46.67"/>
                <measurement group_id="B3" value="179.89" spread="53.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Sleep (Pittsburgh Sleep Quality Index)</title>
          <description>Pittsburgh Sleep Quality Index measures average sleep quality based on self-report over past 7 days. Range is 0 to 21. Higher values are considered worse. There are 7 subscales which are added together.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.2" spread="4.2"/>
                <measurement group_id="B2" value="5.5" spread="3.3"/>
                <measurement group_id="B3" value="6.4" spread="3.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Hot Flashes</title>
          <units>hot flash score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5.5" spread="6.5"/>
                <measurement group_id="B2" value="4.5" spread="5.2"/>
                <measurement group_id="B3" value="5.1" spread="5.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Mood</title>
          <units>CESD global score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6.7" spread="5.5"/>
                <measurement group_id="B2" value="6.0" spread="6.3"/>
                <measurement group_id="B3" value="6.3" spread="5.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo</title>
        <description>Absolute plasma estradiol levels after 4 month course of melatonin or placebo, only 4 month level provided below.</description>
        <time_frame>4 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Taken orally, once per day, at/around 9:00pm
Melatonin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Taken orally, once per day, at/around 9:00pm
Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo</title>
            <description>Absolute plasma estradiol levels after 4 month course of melatonin or placebo, only 4 month level provided below.</description>
            <units>pg/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.59" spread="3.42"/>
                  <measurement group_id="O2" value="3.39" spread="2.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance</title>
        <description>To evaluate compliance with a 4 month course of melatonin. Compliance was assessed via pill counts.</description>
        <time_frame>4 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Taken orally, once per day, at/around 9:00pm
Melatonin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Taken orally, once per day, at/around 9:00pm
Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Compliance</title>
            <description>To evaluate compliance with a 4 month course of melatonin. Compliance was assessed via pill counts.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mood, Sleep Quality and Menopausal Symptoms From Baseline to 4 Months</title>
        <description>Mood was assessed by the Center for Epidemiologic studies Depression Scale. The scale measures depressive symptoms in 20 items. Each question has a 4 point answer (0-3) so the scale range is 0-60. A higher score indicates more depression. Sleep quality was assessed by the Pittsburgh Sleep Quality Index. There are 19 questions each with a 3 point answer. The questions are grouped into 7 subscales and each has a value from 0-3. The 7 subscales are then added together to yield a global score with a range of 0-21. Higher scores indicate worse sleep. Menopausal symptoms were assessed by NCCTG Hot Flash diary. Subjects track the number and severity of hot flashes daily for 1 week. Subjects grade the severity of the hot flashes on a scale of 1-4, with 1 being mild and 4 very severe. Frequency and the severity determine the score . The minimum score is 0 (no hot flashes) and there is no maximum score. A higher score indicates more severe hot flashes. There are no subscales or no units.</description>
        <time_frame>baseline and 4 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Taken orally, once per day, at/around 9:00pm
Melatonin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Taken orally, once per day, at/around 9:00pm
Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Mood, Sleep Quality and Menopausal Symptoms From Baseline to 4 Months</title>
            <description>Mood was assessed by the Center for Epidemiologic studies Depression Scale. The scale measures depressive symptoms in 20 items. Each question has a 4 point answer (0-3) so the scale range is 0-60. A higher score indicates more depression. Sleep quality was assessed by the Pittsburgh Sleep Quality Index. There are 19 questions each with a 3 point answer. The questions are grouped into 7 subscales and each has a value from 0-3. The 7 subscales are then added together to yield a global score with a range of 0-21. Higher scores indicate worse sleep. Menopausal symptoms were assessed by NCCTG Hot Flash diary. Subjects track the number and severity of hot flashes daily for 1 week. Subjects grade the severity of the hot flashes on a scale of 1-4, with 1 being mild and 4 very severe. Frequency and the severity determine the score . The minimum score is 0 (no hot flashes) and there is no maximum score. A higher score indicates more severe hot flashes. There are no subscales or no units.</description>
            <units>change in PSQI score</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Change in PSQI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.9" spread="2.4"/>
                  <measurement group_id="O2" value="-0.1" spread="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in CESD</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="4.6"/>
                  <measurement group_id="O2" value="-0.0" spread="5.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in Hot Flash Score</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="6.1"/>
                  <measurement group_id="O2" value="-1.3" spread="3.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 4 months of study treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>Taken orally, once per day, at/around 9:00pm
Melatonin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Taken orally, once per day, at/around 9:00pm
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bad Dreams</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wendy Chen</name_or_title>
      <organization>DFCI</organization>
      <phone>617-632-3800</phone>
      <email>wychen@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
